Local Inflammation Exacerbates the Severity of Staphylococcus aureus Skin Infection

Department of Pediatrics, University of Chicago, Chicago, Illinois, United States of America.
PLoS ONE (Impact Factor: 3.23). 07/2013; 8(7):e69508. DOI: 10.1371/journal.pone.0069508
Source: PubMed


Staphylococcus aureus is the leading cause of skin infections. In a mouse model of S. aureus skin infection, we found that lesion size did not correlate with bacterial burden. Athymic nude mice had smaller skin lesions that contained lower levels of myeloperoxidase, IL-17A, and CXCL1, compared with wild type mice, although there was no difference in bacterial burden. T cell deficiency did not explain the difference in lesion size, because TCR βδ (-/-) mice did not have smaller lesions, and adoptive transfer of congenic T cells into athymic nude mice prior to infection did not alter lesion size. The differences observed were specific to the skin, because mortality in a pneumonia model was not different between wild type and athymic nude mice. Thus, the clinical severity of S. aureus skin infection is driven by the inflammatory response to the bacteria, rather than bacterial burden, in a T cell independent manner.

Download full-text


Available from: Anita Chong, Jan 16, 2015
  • Source
    • "The demonstration that larger skin lesions also had increased numbers of bacteria recovered suggests a defect in bacterial clearance. Although the kinetics of bacterial clearance and the role of bacterial burden in the severity of dermonecrotic lesions remains to be fully elucidated[31,32], we and others have demonstrated that large differences in lesion severity (e.g., WT vs. µMT mice and strain 923 vs. ∆sbi or ∆sbi∆spa in this study) are accompanied by differences in bacterial burden and local inflammatory responses[25,333435. While the rapid kinetics suggested a role for nonspecific natural antibodies in defense against S. aureus SSTI, our findings that transfer of naïve BALB/c serum did not restore protection in µMT mice, whereas immune serum did, suggested instead for a role of elicited S. aureus-specific antibodies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recurrent Staphylococcus aureus infections are common, suggesting that immunity elicited by these infections is not protective. We previously reported that S. aureus skin infection (SSTI) elicited antibody-mediated immunity against secondary SSTI in BALB/c mice. In this study, we investigated the role of humoral immunity and the IgG-binding proteins Sbi and SpA in S. aureus SSTI. We found that B lymphocyte-deficient μMT mice were highly susceptible to infection, compared with congenic BALB/c mice. Importantly, transfer of immune serum protected μMT mice, demonstrating an appropriate response to protective antibody. We found that deletion of sbi, but not spa, impaired virulence, as assessed by skin lesion severity, and that Sbi-mediated virulence required B lymphocytes/antibody. Furthermore, neither Sbi nor SpA impaired the elicited antibody response or protection against secondary SSTI. Taken together, these findings highlight a B lymphocyte/antibody-dependent role of Sbi in the pathogenesis of S. aureus SSTI, and demonstrate that neither Sbi nor SpA interfered with elicited antibody-mediated immunity.
    Preview · Article · Jan 2016 · Pathogens
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. RR (2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of proinflammatory cytokines, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, in methicillin-resistant Staphylococcus aureus USA 300-0114 skin lesions. Furthermore, the combined therapy of RRIKA (1%) and lysostaphin (0.5%) had significantly higher antistaphylococcal and anti-inflammatory activity compared to monotherapy. This study supports the potential use of these peptides for topical treatment of methicillin-resistant Staphylococcus aureus skin infections.
    Full-text · Article · Oct 2014 · Drug Design, Development and Therapy
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Staphylococcus aureus (S. aureus) is a virulent bacterium that abundantly colonizes inflammatory skin diseases. Since S. aureus infections occur in an impaired skin barrier, it is important to understand the protective mechanism through cutaneous immune responses against S. aureus infections and the interaction with Staphylococcal virulence factors. In this review, we summarize not only the pathogenesis and key elements of S. aureus skin infections, but also the cutaneous immune system against its infections and colonization. The information obtained from this area may provide the groundwork for further immunomodulatory therapies or vaccination strategies to prevent S. aureus infections.
    Full-text · Article · Mar 2014
Show more